Michael Wyzga
Chairman at MEREO BIOPHARMA GROUP PLC
Net worth: 86 634 $ as of 29/04/2024
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Denise Scots-Knight | M | 64 | 21 years | |
Paula Ragan | M | 54 |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | 16 years |
John Lewicki | M | 72 | 20 years | |
Michael Franken | M | 59 |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | 3 years |
Deepa Pakianathan | M | 59 | 16 years | |
Jeno Gyuris | M | 64 |
Tvardi Therapeutics, Inc.
Tvardi Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Tvardi Therapeutics, Inc. develops and commercializes medicines for the treatment of diverse cancers, chronic inflammatory and fibrotic diseases. The company was founded by David J. Tweardy and Ronald A. DePinho in 2017 and is headquartered in Houston, TX.
Sporos Bioventures, Inc.
Sporos Bioventures, Inc. Medical/Nursing ServicesHealth Services Sporos Bioventures, Inc. is a private biopharmaceutical company based in Houston, TX. Sporos Bioventures, Inc. aims to transform the drug development process by identifying novel disease mechanisms and strategically deploying talent, capital, and access to operational resources to catalyze the development of breakthrough medicines. Sporos' current pipeline is diversified across three business units and includes multiple clinical-stage candidates that are being investigated for the treatment of multiple indications in cancer and immune disease. The company provides centralized expertise, resources, and core infrastructure so that the portfolio companies can focus primarily on their research development programs. The company was founded by Peter Feinberg, Ronald A. DePinho, Jeno Gyuris, Joseph Kekst, Harold Levy, Alex M. Cranberg, Louis Feinberg, Michael S. Wyzga, Dana Levy, and the CEO is Stephen Rubino. | 6 years |
Françoise de Craecker | F | 62 | 3 years | |
Pierre Jacquet | M | 57 | 5 years | |
Ashish Nimgaonkar | M | - |
Glyscend, Inc.
Glyscend, Inc. Pharmaceuticals: MajorHealth Technology Glyscend, Inc. engages in the development of therapeutics for treating metabolic diseases. It focuses on providing patients with an effective strategy to keep glucose levels under control and eliminate potential side effects like weight gain and hypoglycemia. The company was founded by Kevin Colbert in September 2014 and is headquartered in Baltimore, MD. | - |
Laurence Rodriguez | F | 56 | 3 years | |
Jonathan Quick | M | - | 5 years | |
Stephen Rubino | M | 65 |
Sporos Bioventures, Inc.
Sporos Bioventures, Inc. Medical/Nursing ServicesHealth Services Sporos Bioventures, Inc. is a private biopharmaceutical company based in Houston, TX. Sporos Bioventures, Inc. aims to transform the drug development process by identifying novel disease mechanisms and strategically deploying talent, capital, and access to operational resources to catalyze the development of breakthrough medicines. Sporos' current pipeline is diversified across three business units and includes multiple clinical-stage candidates that are being investigated for the treatment of multiple indications in cancer and immune disease. The company provides centralized expertise, resources, and core infrastructure so that the portfolio companies can focus primarily on their research development programs. The company was founded by Peter Feinberg, Ronald A. DePinho, Jeno Gyuris, Joseph Kekst, Harold Levy, Alex M. Cranberg, Louis Feinberg, Michael S. Wyzga, Dana Levy, and the CEO is Stephen Rubino. | - |
Mary DiBiase | M | 63 | 7 years | |
Adam Mostafa | M | 44 | 6 years | |
Jeffrey Thielman | M | - |
International Institute of New England, Inc.
International Institute of New England, Inc. Services to the Health IndustryHealth Services International Institute of New England, Inc. operates as a non-profit organization serving immigrants, refugees, asylees, and other vulnerable populations. Its services include refugee resettlement, case management, health services navigation, employment, education and literacy and citizenship programming. The company was founded in 1910 and is headquartered in Boston, MA. | 9 years |
Marc Elia | M | 48 | 2 years | |
Sapan Shah | M | - |
Glyscend, Inc.
Glyscend, Inc. Pharmaceuticals: MajorHealth Technology Glyscend, Inc. engages in the development of therapeutics for treating metabolic diseases. It focuses on providing patients with an effective strategy to keep glucose levels under control and eliminate potential side effects like weight gain and hypoglycemia. The company was founded by Kevin Colbert in September 2014 and is headquartered in Baltimore, MD. | 1 years |
John P. Richard | M | 66 |
Altus Pharmaceuticals, Inc.
Altus Pharmaceuticals, Inc. BiotechnologyHealth Technology Altus Pharmaceuticals, Inc. develops therapeutic products for gastrointestinal and metabolic diseases. Its principal activity is protein crystallization which is used to develop therapeutic products for gastrointestinal and metabolic diseases. The company was founded in October 1992 and is headquartered in Waltham, MA. | 18 years |
Charles Sermon | M | 55 | 9 years | |
William Duke | M | 51 |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | 3 years |
Gary Bridger | M | 61 |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | 8 years |
Deborah Rathjen | M | - |
Carina Biotech Pty Ltd.
Carina Biotech Pty Ltd. BiotechnologyHealth Technology Carina Biotech Pty Ltd. is an immuno-oncology company based in Mawson Lakes, Australia. The Australian company is developing CAR-T and other adoptive cell therapies to treat solid cancers. Carina Biotech has a deep pipeline of CAR-T programs, including its LGR5-targeted CAR-T cell therapy CNA3103 for advanced colorectal cancer. The private company aims to improve access to and infiltration of solid cancers by CAR-containing cells, resulting in more potent and specific cancer killing and reduced off-target effects. Carina Biotech also has a fully integrated, proprietary manufacturing process that has both reduced manufacturing time and improved CAR-T cell quality, capable of delivering robust “serial-killing” CAR-T cells to patients. The CEO of the company is Deborah A. Rathjen. | - |
Magali Taiel | M | - | 6 years | |
James Herriott | M | 44 | 6 years | |
Rita McDonough | F | - |
International Institute of New England, Inc.
International Institute of New England, Inc. Services to the Health IndustryHealth Services International Institute of New England, Inc. operates as a non-profit organization serving immigrants, refugees, asylees, and other vulnerable populations. Its services include refugee resettlement, case management, health services navigation, employment, education and literacy and citizenship programming. The company was founded in 1910 and is headquartered in Boston, MA. | 11 years |
David McGirr | M | 69 | 7 years | |
Adrian Adams | M | 73 | 6 years | |
Michael Rogers | M | 64 | 6 years | |
Jill Andersen | F | 51 | 3 years | |
Murray Stewart | M | 63 | 5 years | |
Louis Feinberg | M | - |
Sporos Bioventures, Inc.
Sporos Bioventures, Inc. Medical/Nursing ServicesHealth Services Sporos Bioventures, Inc. is a private biopharmaceutical company based in Houston, TX. Sporos Bioventures, Inc. aims to transform the drug development process by identifying novel disease mechanisms and strategically deploying talent, capital, and access to operational resources to catalyze the development of breakthrough medicines. Sporos' current pipeline is diversified across three business units and includes multiple clinical-stage candidates that are being investigated for the treatment of multiple indications in cancer and immune disease. The company provides centralized expertise, resources, and core infrastructure so that the portfolio companies can focus primarily on their research development programs. The company was founded by Peter Feinberg, Ronald A. DePinho, Jeno Gyuris, Joseph Kekst, Harold Levy, Alex M. Cranberg, Louis Feinberg, Michael S. Wyzga, Dana Levy, and the CEO is Stephen Rubino. | - |
Freda Lewis-Hall | M | 69 | 4 years | |
Harold Levy | M | - |
Sporos Bioventures, Inc.
Sporos Bioventures, Inc. Medical/Nursing ServicesHealth Services Sporos Bioventures, Inc. is a private biopharmaceutical company based in Houston, TX. Sporos Bioventures, Inc. aims to transform the drug development process by identifying novel disease mechanisms and strategically deploying talent, capital, and access to operational resources to catalyze the development of breakthrough medicines. Sporos' current pipeline is diversified across three business units and includes multiple clinical-stage candidates that are being investigated for the treatment of multiple indications in cancer and immune disease. The company provides centralized expertise, resources, and core infrastructure so that the portfolio companies can focus primarily on their research development programs. The company was founded by Peter Feinberg, Ronald A. DePinho, Jeno Gyuris, Joseph Kekst, Harold Levy, Alex M. Cranberg, Louis Feinberg, Michael S. Wyzga, Dana Levy, and the CEO is Stephen Rubino. | - |
Dana Levy | F | - |
Sporos Bioventures, Inc.
Sporos Bioventures, Inc. Medical/Nursing ServicesHealth Services Sporos Bioventures, Inc. is a private biopharmaceutical company based in Houston, TX. Sporos Bioventures, Inc. aims to transform the drug development process by identifying novel disease mechanisms and strategically deploying talent, capital, and access to operational resources to catalyze the development of breakthrough medicines. Sporos' current pipeline is diversified across three business units and includes multiple clinical-stage candidates that are being investigated for the treatment of multiple indications in cancer and immune disease. The company provides centralized expertise, resources, and core infrastructure so that the portfolio companies can focus primarily on their research development programs. The company was founded by Peter Feinberg, Ronald A. DePinho, Jeno Gyuris, Joseph Kekst, Harold Levy, Alex M. Cranberg, Louis Feinberg, Michael S. Wyzga, Dana Levy, and the CEO is Stephen Rubino. | - |
Marie Payton | F | - | 5 years | |
Jorge Garces | M | 52 | 3 years | |
Remus Vezan | M | - |
Carina Biotech Pty Ltd.
Carina Biotech Pty Ltd. BiotechnologyHealth Technology Carina Biotech Pty Ltd. is an immuno-oncology company based in Mawson Lakes, Australia. The Australian company is developing CAR-T and other adoptive cell therapies to treat solid cancers. Carina Biotech has a deep pipeline of CAR-T programs, including its LGR5-targeted CAR-T cell therapy CNA3103 for advanced colorectal cancer. The private company aims to improve access to and infiltration of solid cancers by CAR-containing cells, resulting in more potent and specific cancer killing and reduced off-target effects. Carina Biotech also has a fully integrated, proprietary manufacturing process that has both reduced manufacturing time and improved CAR-T cell quality, capable of delivering robust “serial-killing” CAR-T cells to patients. The CEO of the company is Deborah A. Rathjen. | 1 years |
Elsy Boglioli Hofman | F | 42 | 4 years | |
Simone Seiter | M | 57 | 7 years | |
Imran Alibhai | M | - |
Tvardi Therapeutics, Inc.
Tvardi Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Tvardi Therapeutics, Inc. develops and commercializes medicines for the treatment of diverse cancers, chronic inflammatory and fibrotic diseases. The company was founded by David J. Tweardy and Ronald A. DePinho in 2017 and is headquartered in Houston, TX. | 6 years |
Kathleen Sebelius | F | 75 | 5 years | |
Sara Cotter | F | 43 | 1 years | |
Paul Clancy | M | 62 | 3 years | |
Alison Lawton | F | 62 | 4 years | |
Bill Aliski | M | 75 | 5 years | |
Anders Olof Adolf Ekblom | M | 70 | 9 years | |
Cynthia Dohmen LaConte | F | - |
Dohmen Co.
Dohmen Co. Data Processing ServicesTechnology Services Dohmen Co. operates as a retail pharmacy agency that provides outsourced healthcare services. Its services include supply chain, customer and patient support, technology, financial, consulting, and quality and regulatory services. The company was founded by Friedrich W. Dohmen in 1858 and is headquartered in Milwaukee, WI. | 29 years |
Charlie Latham | M | 69 |
Carina Biotech Pty Ltd.
Carina Biotech Pty Ltd. BiotechnologyHealth Technology Carina Biotech Pty Ltd. is an immuno-oncology company based in Mawson Lakes, Australia. The Australian company is developing CAR-T and other adoptive cell therapies to treat solid cancers. Carina Biotech has a deep pipeline of CAR-T programs, including its LGR5-targeted CAR-T cell therapy CNA3103 for advanced colorectal cancer. The private company aims to improve access to and infiltration of solid cancers by CAR-containing cells, resulting in more potent and specific cancer killing and reduced off-target effects. Carina Biotech also has a fully integrated, proprietary manufacturing process that has both reduced manufacturing time and improved CAR-T cell quality, capable of delivering robust “serial-killing” CAR-T cells to patients. The CEO of the company is Deborah A. Rathjen. | - |
Christine Regan Lindenboom | F | 43 | 2 years | |
Annalisa Jenkins | M | 58 | 2 years | |
Cynthia Smith | F | 55 | 6 years | |
Zoltan A. Csimma | M | 82 |
International Institute of New England, Inc.
International Institute of New England, Inc. Services to the Health IndustryHealth Services International Institute of New England, Inc. operates as a non-profit organization serving immigrants, refugees, asylees, and other vulnerable populations. Its services include refugee resettlement, case management, health services navigation, employment, education and literacy and citizenship programming. The company was founded in 1910 and is headquartered in Boston, MA.
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | - |
Peter Feinberg | M | 63 |
Sporos Bioventures, Inc.
Sporos Bioventures, Inc. Medical/Nursing ServicesHealth Services Sporos Bioventures, Inc. is a private biopharmaceutical company based in Houston, TX. Sporos Bioventures, Inc. aims to transform the drug development process by identifying novel disease mechanisms and strategically deploying talent, capital, and access to operational resources to catalyze the development of breakthrough medicines. Sporos' current pipeline is diversified across three business units and includes multiple clinical-stage candidates that are being investigated for the treatment of multiple indications in cancer and immune disease. The company provides centralized expertise, resources, and core infrastructure so that the portfolio companies can focus primarily on their research development programs. The company was founded by Peter Feinberg, Ronald A. DePinho, Jeno Gyuris, Joseph Kekst, Harold Levy, Alex M. Cranberg, Louis Feinberg, Michael S. Wyzga, Dana Levy, and the CEO is Stephen Rubino. | 4 years |
Shacey Petrovic | F | 50 | 4 years | |
Sujal Shah | M | 50 |
Tvardi Therapeutics, Inc.
Tvardi Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Tvardi Therapeutics, Inc. develops and commercializes medicines for the treatment of diverse cancers, chronic inflammatory and fibrotic diseases. The company was founded by David J. Tweardy and Ronald A. DePinho in 2017 and is headquartered in Houston, TX. | 3 years |
Maritza McIntyre | M | 58 | 5 years | |
Steven Gilman | M | 71 | 6 years | |
Alex M. Cranberg | M | - |
Sporos Bioventures, Inc.
Sporos Bioventures, Inc. Medical/Nursing ServicesHealth Services Sporos Bioventures, Inc. is a private biopharmaceutical company based in Houston, TX. Sporos Bioventures, Inc. aims to transform the drug development process by identifying novel disease mechanisms and strategically deploying talent, capital, and access to operational resources to catalyze the development of breakthrough medicines. Sporos' current pipeline is diversified across three business units and includes multiple clinical-stage candidates that are being investigated for the treatment of multiple indications in cancer and immune disease. The company provides centralized expertise, resources, and core infrastructure so that the portfolio companies can focus primarily on their research development programs. The company was founded by Peter Feinberg, Ronald A. DePinho, Jeno Gyuris, Joseph Kekst, Harold Levy, Alex M. Cranberg, Louis Feinberg, Michael S. Wyzga, Dana Levy, and the CEO is Stephen Rubino. | - |
Janice Olson | F | - | 3 years | |
Grace Lochhead | F | - | 3 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
René Russo | M | 49 | 7 years | |
Ronald Renaud | M | 55 | 11 years | |
Maneesh K. Arora | M | 55 | 9 years | |
Cecilia Jones | F | 49 |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | 8 years |
Yvonne Li | F | 64 | 12 years | |
Robert A. Shalwitz | M | 69 | 7 years | |
Mark Enyedy | M | 60 | 4 years | |
Richard A. Moscicki | M | 72 |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | 24 years |
Jim Woody | M | 81 | 10 years | |
Bernard Gilly | M | 67 | 12 years | |
Tillman Gerngross | M | 60 | 2 years | |
Paul Hastings | M | 64 | 12 years | |
Henri A. Termeer | M | 78 |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | 28 years |
Georges Gemayel | M | 64 |
Altus Pharmaceuticals, Inc.
Altus Pharmaceuticals, Inc. BiotechnologyHealth Technology Altus Pharmaceuticals, Inc. develops therapeutic products for gastrointestinal and metabolic diseases. Its principal activity is protein crystallization which is used to develop therapeutic products for gastrointestinal and metabolic diseases. The company was founded in October 1992 and is headquartered in Waltham, MA.
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | 6 years |
Perry Karsen | M | 69 | 3 years | |
Bryan Yoon | M | 46 | 1 years | |
Daniella Beckman | F | 45 | 6 years | |
Alastair MacKinnon | M | 53 | 7 years | |
Jeffrey Elliott | M | 46 | 8 years | |
Owen Hughes | M | 49 | 9 years | |
Scott Canute | M | 63 |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | 5 years |
Peter John Fellner | M | 80 | 7 years | |
Tom R. Hodgson | M | 82 | 12 years | |
Eric S. Hoffman | M | 54 | 3 years | |
Robert J. Stagg | M | - | - | |
Christopher Viehbacher | M | 64 |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | - |
Mark A. Kay | M | 66 | 8 years | |
Jim Manzi | M | 72 |
Lotus Development Corp.
Lotus Development Corp. Packaged SoftwareTechnology Services Lotus Development Corp. was an American software company. The company was famous for their groundbreaking Lotus 1-2-3 spreadsheet application, which was the killer application in the early days of the IBM PC which helped spread the adoption of the PC. The company also provided one of the more powerful groupware systems, Lotus Notes. The company was headquartered in Cambridge, MA | 11 years |
Michael Gray | M | 53 | 3 years | |
David Hering | M | 49 | 3 years | |
Kyle Chiang | M | 44 | 5 years | |
Daniel O’Connell | M | 44 | 3 years | |
Jon Root | M | 64 | 15 years | |
Brian Luque | M | - | - | |
Richard Jones | M | 58 | 3 years | |
Erez Chimovits | M | 60 | 4 years | |
Sunil Patel | M | 52 | 9 years | |
Paul Blackburn | M | - | 5 years | |
Jonathan Lieber | M | 54 |
Altus Pharmaceuticals, Inc.
Altus Pharmaceuticals, Inc. BiotechnologyHealth Technology Altus Pharmaceuticals, Inc. develops therapeutic products for gastrointestinal and metabolic diseases. Its principal activity is protein crystallization which is used to develop therapeutic products for gastrointestinal and metabolic diseases. The company was founded in October 1992 and is headquartered in Waltham, MA. | 7 years |
David N. Standring | M | 73 | 13 years |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 84 | 84.00% |
United Kingdom | 12 | 12.00% |
France | 7 | 7.00% |
Australia | 3 | 3.00% |
Netherlands | 1 | 1.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Michael Wyzga
- Personal Network